Compare DAN & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAN | OGN |
|---|---|---|
| Founded | 1904 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | N/A | N/A |
| Metric | DAN | OGN |
|---|---|---|
| Price | $22.35 | $7.50 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 4 |
| Target Price | ★ $26.00 | $15.75 |
| AVG Volume (30 Days) | 1.7M | ★ 6.3M |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.79% | 1.07% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.39 | ★ 1.91 |
| Revenue | ★ $9,957,000,000.00 | $6,301,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $57.57 | ★ $3.92 |
| Revenue Growth | ★ 17.78 | N/A |
| 52 Week Low | $10.11 | $6.18 |
| 52 Week High | $22.91 | $17.23 |
| Indicator | DAN | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.98 | 46.46 |
| Support Level | $22.05 | $6.95 |
| Resistance Level | $22.91 | $7.86 |
| Average True Range (ATR) | 0.81 | 0.35 |
| MACD | 0.14 | 0.12 |
| Stochastic Oscillator | 85.32 | 59.89 |
Dana Inc is engaged in the designing and manufacturing of efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company has four operating segments: Light Vehicles, Power Technologies, Commercial Vehicle, and Off-Highway. The Light Vehicles segment generates the majority portion of revenue by providing products to support light vehicle OEMs. Its products are designed for light trucks, SUVs, CUVs, vans, and passenger cars.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.